This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

StemCells, Inc. Strengthens Product Development Team And Appoints Executive To Focus On Scientific And Strategic Alliances

Dr. Tsukamoto has been a groundbreaking researcher in the field of stem cell biology for more than twenty years. She joined the Company in February 1998 as Senior Director, Scientific Operations, and has held several leadership roles at the Company, most recently as Executive Vice President of Research and Development since September 2008. Dr. Tsukamoto was a co-discoverer of the human hematopoietic stem cell while at SyStemix, Inc., and played a leading role at StemCells in the isolation of the human neural stem cell as well as populations of human liver and pancreatic cells with stem cell-like properties.  Dr. Tsukamoto received her doctorate from the University of California, Los Angeles, and did postdoctoral research at the University of California, San Francisco. 

In his new role, Dr. Salinas will focus on accelerating completion of the Company's ongoing trials in spinal cord injury and age-related macular degeneration, as well as advancing the Company's plans for a Phase II study in Pelizaeus-Merzbacher disease. Dr. Salinas has more than 20 years of experience and expertise developing therapeutic products for central nervous system (CNS) disorders in many key jurisdictions worldwide, including the United States, Canada, the European Union, and Japan. Under his leadership, 15 programs obtained regulatory approval in the United States and other major international markets. Prior to joining StemCells, Dr. Salinas was Executive Vice President, Head of Development, and Chief Medical Officer of Elan Pharmaceuticals. Before joining Elan, Dr. Salinas was Senior Vice President, Research and Development and Chief Medical Officer of Adolor Coproration; Executive Vice President, Speciality Pharma, Research and Development and Chief Scientific Officer of Shire plc; and held roles of increasing responsibility in research and development at Wyeth-Ayerst Research, including head of worldwide CNS product development. Dr. Salinas earned his medical degree from the University of Buenos Aires, Argentina, performed a residency in psychiatry in Paris at the Clinique des Maladies Mentales et de l'Encéphale, and obtained a master's degree in pharmacology from the Université Pierre et Marie Curie, Académie de Paris, France.  

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,162.99 +121.45 0.67%
S&P 500 2,123.48 +19.28 0.92%
NASDAQ 5,106.5930 +73.8420 1.47%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs